ICML 2023 | The use of clonoSEQ to monitor MRD in patients with LBCL treated with axi-cel in ZUMA-7
Jason Westin, MD, FACP, The University of Texas MD Anderson Cancer Center, Houston, TX, explores the challenges in determining which patients with large B-cell lymphoma (DLBCL) are likely to benefit from treatment with axicabtagene ciloleucel (axi-cel). The use of measurable residual disease (MRD) assays, such as the clonoSEQ assay, has been explored for MRD detection in the ZUMA-7 study (NCT03391466). However, these assays currently lack the predictive power required to predict outcomes with CAR-T therapy. This interview took place at the 17th International Conference on Malignant Lymphoma (ICML), held in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
